Studio clinico NCT06667908 · Carcinoma, Non-Small-Cell Lung
Studio clinico NCT06667908 (fase II) risulta «in reclutamento» su ClinicalTrials.gov.
Patologia: Carcinoma, Non-Small-Cell Lung · Interventi registrati: JNJ-90301900, Durvalumab, Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin, Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel · Date registrate (fonte): 2024-12-06, 2028-12-31, 2024-10-31, 2026-08-28.
Sintesi dello studio (fonte: ClinicalTrials.gov, testo originale in inglese):
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.